HomeCompareHKTTF vs JNJ

HKTTF vs JNJ: Dividend Comparison 2026

HKTTF yields 7.40% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HKTTF wins by $20.2K in total portfolio value
10 years
HKTTF
HKTTF
● Live price
7.40%
Share price
$1.38
Annual div
$0.10
5Y div CAGR
12.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$50.5K
Annual income
$5,539.96
Full HKTTF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — HKTTF vs JNJ

📍 HKTTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHKTTFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HKTTF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HKTTF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HKTTF
Annual income on $10K today (after 15% tax)
$628.74/yr
After 10yr DRIP, annual income (after tax)
$4,708.97/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, HKTTF beats the other by $722.98/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HKTTF + JNJ for your $10,000?

HKTTF: 50%JNJ: 50%
100% JNJ50/50100% HKTTF
Portfolio after 10yr
$40.4K
Annual income
$5,114.68/yr
Blended yield
12.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

HKTTF
No analyst data
Altman Z
1.5
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HKTTF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHKTTFJNJ
Forward yield7.40%2.13%
Annual dividend / share$0.10$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR12.6%28%
Portfolio after 10y$50.5K$30.3K
Annual income after 10y$5,539.96$4,689.40
Total dividends collected$25.0K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HKTTF vs JNJ ($10,000, DRIP)

YearHKTTF PortfolioHKTTF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,533$832.89$10,592$272.30+$941.00HKTTF
2$13,351$1,010.84$11,289$357.73+$2.1KHKTTF
3$15,517$1,231.44$12,123$472.89+$3.4KHKTTF
4$18,109$1,506.13$13,141$629.86+$5.0KHKTTF
5$21,227$1,849.74$14,408$846.81+$6.8KHKTTF
6$24,994$2,281.64$16,021$1,151.60+$9.0KHKTTF
7$29,571$2,827.21$18,122$1,588.22+$11.4KHKTTF
8$35,161$3,519.97$20,930$2,228.20+$14.2KHKTTF
9$42,027$4,404.41$24,792$3,191.91+$17.2KHKTTF
10$50,509$5,539.96$30,274$4,689.40+$20.2KHKTTF

HKTTF vs JNJ: Complete Analysis 2026

HKTTFStock

HKT Trust and HKT Limited provides telecommunications services in Hong Kong, Mainland China, and internationally. It operates through Telecommunications Services, Mobile, Pay TV, and Other Businesses segments. The Telecommunications Services segment offers telecommunications and related services, including local telephony, local data and broadband, and international telecommunications, as well as enterprise solutions; and other telecommunications businesses, such as customer premises equipment sales, outsourcing, consulting, and contact centers. The Mobile segment provides mobile telecommunications services. The Pay TV segment offers interactive pay-TV services. The Other Businesses segment provides financial services, such as mobile payments, merchant services, O2O solutions, and a mobile financing platform; and The Club, a loyalty program. The company also offers 5G, cloud computing, Internet of Things, and artificial intelligence solutions to enterprises; web services; network-based telecommunications and satellite-based services; outsourced contact center services; customer and consultancy services; customer relationship and customer contact management solutions and services; telecommunications call center services; and insurance and reinsurance services. In addition, it provides system integration, software development, and technical consultancy services; and sells mobile handsets and accessories, as well as telecommunication products and services. Further, the company sells advertising in various telephone directories and on the Internet; distributes media content; and publishes directories. The company was incorporated in 2011 and is headquartered in Quarry Bay, Hong Kong. HKT Trust and HKT Limited is a subsidiary of PCCW Limited.

Full HKTTF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this HKTTF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HKTTF vs SCHDHKTTF vs JEPIHKTTF vs OHKTTF vs KOHKTTF vs MAINHKTTF vs ABBVHKTTF vs MRKHKTTF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.